tetano
Editor, Senior Moderator
Autoimmun Rev. 2020 May 4:102566. doi: 10.1016/j.autrev.2020.102566. [Epub ahead of print]
Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis.
Gendelman O[SUP]1[/SUP], Amital H[SUP]2[/SUP], Bragazzi NL[SUP]3[/SUP], Watad A[SUP]1[/SUP], Chodick G[SUP]4[/SUP].
Author information
Abstract
BACKGROUND:
Some disease-modifying agents commonly used to treat patients with rheumatic diseases/autoimmune disorders, such as hydroxychloroquine and colchicine, are under investigation as potential therapies for the "coronavirus disease 2019" (COVID-19). However, the role of such agents as prophylactic tools is still not clear.
METHODS:
This is a retrospective study based on a large healthcare computerized database including all patients that were screened for the "Severe Acute Respiratory Syndrome Coronavirus type 2" (SARS-CoV-2) in the study period from February 23rd 2020 to March 31st 2020. A comparison was conducted between subjects tested positive for SARS-CoV-2 and those found negative in terms of rate of administration of hydroxychloroquine/colchicine therapy.
RESULTS:
An overall sample of 14,520 subjects were screened for SARS-CoV-2 infection and 1317 resulted positive. No significant difference was found in terms of rates of usage of hydroxychloroquine or colchicine between those who were found positive for SARS-CoV-2 and those who were found negative (0.23% versus 0.25% for hydroxychloroquine, and 0.53% versus 0.48% for colchicine, respectively).
CONCLUSION:
These findings raise doubts regarding the protective role of these medications in the battle against SARS-CoV-2 infection.
Copyright ? 2020. Published by Elsevier B.V.
KEYWORDS:
Autoimmunity; COVID-19; Colchicine; Hydroxychloroquine; Rheumatic disease; SARS-CoV-2
PMID:32380315DOI:10.1016/j.autrev.2020.102566
Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis.
Gendelman O[SUP]1[/SUP], Amital H[SUP]2[/SUP], Bragazzi NL[SUP]3[/SUP], Watad A[SUP]1[/SUP], Chodick G[SUP]4[/SUP].
Author information
Abstract
BACKGROUND:
Some disease-modifying agents commonly used to treat patients with rheumatic diseases/autoimmune disorders, such as hydroxychloroquine and colchicine, are under investigation as potential therapies for the "coronavirus disease 2019" (COVID-19). However, the role of such agents as prophylactic tools is still not clear.
METHODS:
This is a retrospective study based on a large healthcare computerized database including all patients that were screened for the "Severe Acute Respiratory Syndrome Coronavirus type 2" (SARS-CoV-2) in the study period from February 23rd 2020 to March 31st 2020. A comparison was conducted between subjects tested positive for SARS-CoV-2 and those found negative in terms of rate of administration of hydroxychloroquine/colchicine therapy.
RESULTS:
An overall sample of 14,520 subjects were screened for SARS-CoV-2 infection and 1317 resulted positive. No significant difference was found in terms of rates of usage of hydroxychloroquine or colchicine between those who were found positive for SARS-CoV-2 and those who were found negative (0.23% versus 0.25% for hydroxychloroquine, and 0.53% versus 0.48% for colchicine, respectively).
CONCLUSION:
These findings raise doubts regarding the protective role of these medications in the battle against SARS-CoV-2 infection.
Copyright ? 2020. Published by Elsevier B.V.
KEYWORDS:
Autoimmunity; COVID-19; Colchicine; Hydroxychloroquine; Rheumatic disease; SARS-CoV-2
PMID:32380315DOI:10.1016/j.autrev.2020.102566